1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sage NMDA Modulator Fails In Alzheimer’s Months After Parkinson’s Disappointment

 
• By Joseph Haas

Dalzanemdor missed its primary endpoint in a Phase II Parkinson’s study, Sage announced, following April’s Phase II miss in Alzheimer’s. Phase II data in Huntington’s are still expected this year.

Sage missed on the second of three Phase II studies of dalzanemdor in neurodegenerative disease

The misses keep on coming for Sage Therapeutics, Inc. with dalzanemdor, its oral positive allosteric modulator (PAM) of the NMDA receptor, which failed to hit the primary and exploratory endpoints in a Phase II study in Alzheimer’s disease patients, but the biotech said on 8 October that it holds out hope for success with the drug in a Phase II Huntington’s disease trial.

Key Takeaways

  • Sage’s dalzanemdor fails a Phase II study in Alzheimer’s cognitive impairment, six months after the drug missed in a Phase II study in Parkinson’s disease.

  • The biotech is still awaiting Phase II data expected for the drug later this year in Huntington’s disease, where the company thinks it has a better chance of success

In the 174-patient LIGHTWAVE study in Alzheimer’s, dalzanemdor (SAGE-718) failed to meet statistical significance versus placebo on the Weschler Adult Intelligence Scale Fourth Edition (WAIS-IV) test at 84 days, following a miss by the drug on the same test at 42 days in Parkinson’s disease on 17 April. (Also see "Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout" - Scrip, 17 April, 2024

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.